Insulin Use in Dialysis Patients
Yes, insulin is appropriate and often necessary for patients on dialysis, but requires careful dose adjustment to prevent hypoglycemia. 1, 2
Guideline-Based Recommendations
The KDIGO 2022 guidelines explicitly include insulin as an appropriate glucose-lowering agent for patients with type 2 diabetes and chronic kidney disease, specifically noting that this includes patients with eGFR <30 ml/min per 1.73 m² or those treated with dialysis. 1 Insulin appears in the treatment algorithm as one of the additional drug therapy options when first-line agents (metformin and SGLT2 inhibitors) are contraindicated or insufficient. 1
Critical Dose Adjustments Required
For Hemodialysis Patients
Reduce basal insulin by up to 25% on hemodialysis days to prevent hypoglycemia. 3, 4 The evidence demonstrates:
- Blood glucose levels decrease significantly (approximately 35.8%) during and after hemodialysis sessions 5
- A randomized crossover trial showed that reducing insulin by 25% on dialysis days maintained glycemic efficacy while reducing hypoglycemia incidence from 3.3% to 0.7% per dialysis session 4
- Hypoglycemia-related symptoms decreased from 6.9% to 0.7% with dose reduction 4
For Peritoneal Dialysis Patients
Insulin can be administered subcutaneously or intraperitoneally, but intraperitoneal administration may require dose increases of up to 30% due to losses from tubing adsorption and dilution. 3, 6 Key considerations include:
- Dextrose-based dialysate increases systemic glucose absorption, requiring additional insulin 3
- Intraperitoneal insulin administration can prevent major glucose fluctuations and hyperinsulinemia when properly dosed 6
- A basal-bolus insulin regimen (detemir and aspart) in peritoneal dialysis patients reduced HbA1c from 8.41% to 7.68% without increasing hypoglycemia 7
Renal Impairment Considerations
Insulin clearance decreases in renal impairment, necessitating dose adjustments. 2 The FDA labeling for insulin detemir specifically states that insulin requirements may need adjustment in patients with renal impairment, as literature reports show decreased clearance of human insulin in renally impaired patients. 2
Monitoring Recommendations
Use continuous glucose monitoring (CGM) when prescribing insulin or sulfonylureas in dialysis patients to detect glycemic excursions in real time. 8 Recent evidence supports:
- CGM with predictive low glucose alerts prevents hypoglycemic events in this high-risk population 8
- Automated insulin delivery (AID) systems in hemodialysis patients increased time in range from 31.5% to 69.0% compared to conventional insulin therapy without increasing hypoglycemia 8
Common Pitfalls to Avoid
- Do not use the same insulin dose on dialysis and non-dialysis days for hemodialysis patients—this substantially increases hypoglycemia risk 4, 5
- Do not assume standard subcutaneous insulin doses will suffice for peritoneal dialysis patients using intraperitoneal administration—expect to increase doses by 30% 3
- Do not neglect the impact of dialysate dextrose on glucose control in peritoneal dialysis patients 3
- Avoid intravenous or intramuscular administration of long-acting insulin formulations, as absorption is faster and more extensive than intended, risking severe hypoglycemia 2
Practical Algorithm
- Confirm insulin is needed based on glycemic control inadequate with other agents or when other agents are contraindicated 1
- For hemodialysis: Start with standard dosing, then reduce basal insulin by 25% on dialysis days 4
- For peritoneal dialysis: Consider basal-bolus regimen; if using intraperitoneal route, increase dose by 30% to account for losses 3, 7
- Implement CGM to monitor for hypoglycemia, particularly during and after dialysis sessions 8
- Monitor closely during the first 2-4 weeks and adjust based on glucose patterns 4, 5
budget:budget_used